Summary
The HIV epidemic is currently in its third decade without any sign of abating. Tuberculosis (TB) is responsible for a third of all AIDS deaths, 99% of which occur in developing countries. The two epidemics fuel each other, together making up the leading infectious causes of mortality worldwide. Tuberculosis-HIV coinfection presents special diagnostic and therapeutic challenges and constitutes an immense burden on the health care systems of heavily infected countries. Despite major gains that have been made in the past two decades, important questions still remain. To cope with the challenge of TB-HIV coinfection, further research in the design of diagnostic tests for tuberculosis, detection of drug resistantMycobacterium tuberculosis strains in HIV-positive people, as well as development of more effective therapeutic agents and vaccines are urgently needed. It has become evident that this dual epidemic will persist unless comprehensive measures are instituted through the provision of sufficient funding in addition to expanding and strengthening current control strategies adopted by governments and international organizations.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Dolin PJ, Raviglione MC, Kochi A (1994) Global tuberculosis incidence and mortality during 1990–2000. Bull World Health Organ 72: 213–220
Sudre P, ten Dam G, Kochi A (1992) Tuberculosis: a global overview of the situation today. Bull World Health Organ 70: 149–159
Centers for Disease Control and Prevention (1996) Tuberculosis morbidity — United States. 1995. MMWR Morb Mortal Rep 45: 365–370
Barnes PF, Bloch AB, Davidson PT, et al (1991) Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 324: 1644–1650
Houston S, Ray S, Mahari P, et al (1994) The association of tuberculosis and HIV infection in Harare, Zimbabwe. Tubercle and Lung Disease 75: 220–226
Centers for Disease Control and Prevention (1995) Screening for tuberculosis and tuberculosis infection in high-risk populations. MMWR Morb Mortal Rep 44: 19–34
Alland D, Kalkut GE, Moss RA, et al (1994) Transmission of tuberculosis in New York City: an analysis by DNA finger-printing and conventional epidemiologic methods. N Engl J Med 330: 1710–1716
Braun MM, Truman BI, Maquire B, et al (1989) Increasing incidence of tuberculosis in a prison inmate population: association with HIV infection. JAMA 261: 393–397
Beck-Sague C, Dooley SW, Hutton MD, et al (1992) Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections: factors in transmission to staff and HIV-infected patients. JAMA 268: 1280
Nolan CM, Elarth AM, Barr H, et al (1991) An outbreak of tuberculosis in a shelter for homeless men: a description of its evolution and control. Am Rev Respir Dis 143: 257–261
Brudney K, Dobkin J (1991) Resurgent tuberculosis in New York City: human immunodeficiency virus, homelesness and the decline of tuberculosis control programs. Am Rev Respir Dis 144: 745–749
Chaulk CP, Moore-Rice, Rizzo RN, Caisson MD (1995) Eleven years of community-based directly observed therapy for tuberculosis. JAMA 274: 945–951
Centers for Disease Control and Prevention (1998) Tuberculosis morbidity-United States, 1997. MMWR Morb Mortal Rep 47: 253–257
Bayer R, Wilkinson D (1995) Directly observed therapy for tuberculosis: history of an idea. Lancet 345: 1545–1548
Daley CL, Small PM, Schecter GF, et al (1992) An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restriction-fragmentlength polymorphisms. N Engl J Med 326: 231–235
Selwyn PA, Hartel D, Lewis VA, et al (1989) A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 320: 545–550
Asch SM, London AS, Barnes PF, et al (1997) Testing for human immunodeficiency virus infection among tuberculosis patients in Los Angeles. Am J Respir Crit Care Med 155: 378–381
Markowitz N, Hansen NI, Hopewell PC, et al (1997) Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med 126: 123–132
Moreno S, Baraia-Etxaburu J, Bouza E, et al (1993) Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 119: 194–198
Selwyn PA, Sckell BM, Alcabes P, Friedland GH, Klein RS, Schoenbaum EE (1992) High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy, JAMA 268: 504–509
Melnick SL, Sherer R, Louis TA, et al (1994) Survival and disease progression according to gender of patients with HIV. The Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 272: 1915–1921
Graham NM, Cohn S, Galai N, Astemborski J, Nelson KE, Vlahov D (1993) Incidence of mycobacterial infection and disease in HIV-positive and HIV-negative IDUs [Abstract]. Int Conf AIDS 9: 328
Snyder DC, Mohle-Boetani JC, Chandler A, Oliver G, Livermore T, Royce S (1997) A population-based study determining the incidence of tuberculosis attributable to HIV infection. JAIDS 16: 190–194
Mueller G, Whitman S Plummer C (1995) Co-incidence of HIV/AIDS and tuberculosis-Chicago, 1982–1999. MMWR Morb Mortal Rep 44: 227–228
Onorato I, McCombs S, Morgan WM, McGray E (1993) HIV infection in patients attending tuberculosis clinics, United States, 1988–1992 [abstract]. Program and abstracts, 33rd International Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology. Washington DC, p 1363
Sotir MJ, Parrott P, Metchok B, Bock NN, McGowan JE Jr, Ray SM, Miller LP, Blumberg HM (1999) Tuberculosis in the inner city: impact of a continuing epidemic in the 1990s. Clin Infect Dis 29: 1138–1144
Lurie MB (1942) Studies on the mechanism of the immunity in tuberculosis: the fate of tubercle bacilli ingested by mononuclear phagocytes derived from normal and immunized animals. J Exp Med 75: 247–267
Mackaness MB (1969) The influence of immunologically committed lymphoid cells on macrophage activityin vivo. J Exp Med 129: 973–991
Kaufmann SHE (1989) In vitro analysis of the cellular mechanisms involved in immunity to tuberculosis. Rev Infect Dis 2 [Suppl 2]: S448–454
Flesch I, Kaufmann SHE (1987) Mycobacterial growth inhibition by interferon-gamma activated bone marrow macrophages and differential susceptibility among strains ofM. tuberculosis. J Immunol 138: 4408–4413
Newport MJ, Huxley CM, Huston S, et al (1996) A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 335: 1941–1949
Rook GA, Steele J, Fraher, et al (1986) Vitamin D, gamma interferon and control of proliferation of M. tuberculosis by human monocytes. Immunol 57: 159–163
Janis EM, Kaufman SHE, Sheartz RH, Pardoll DM (1989) Activation of gamma/delta T cells in the primary immune response toM. tuberculosis. Science 244: 713–715
Flesch EA, Kaufmann SHE (1988) Attempts to characterize the mechanisms involved in mycobacterial growth inhibition by gamma-interferon-activated bone marrow macrophages. Infect Immun 56: 1464–1469
Zhang M, Gong J, Iyer DV, Jones BE, Modlin RL, Barnes PF (1994) T-cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 94: 2435–2442
Havlir DV, Barnes PF (1999) Tuberculosis in patients with human immunodeficiency virus infection 340: 367–373
Spear GT, Kessler HA, Rothberg L, Phair J, Landay AL (1990) Decreased oxidative burst activity of monocytes from asymptomatic HIV-infected individuals. Clin Immunol Immunopathol 54: 184–191
Smith PD, Ohura K, Masur H, Lane HC, Fauci AS, Wahl SM (1984) Monocyte function in the acquired immune deficiency syndrome. J Clin Invest 74: 2121–2128
Wahl SM, Allen JB, Gartner S, et al (1989) HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes. J Immunol 142: 3553–3559
Barnes PF, Bloch AB, Davidson PT (1991) Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 324: 1644–1650
Nunn P, Brindle R, Capenter L (1992) Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Am Rev Respir Dis 146: 849–854
Stoneburner R, Laroche E, Prevots R (1992) Survival in a cohort of human immunodeficiency virus infected tuberculosis patients in New York City. Arch Intern Med 152: 2033–2037
Whalen CC, Horsburgh R, Hom D, Lahart M, Ellner J (1995) Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 151: 129–135
Goletti D, Weisman R, Jackson W, et al (1996) Effect ofMycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 157: 1271–1278
Zhang Y, Broser M, Rom WN (1994) Activation of the interleukin-6-gene byMycobacterium tuberculosis or lipopoly saccharide is mediated by NF-IL6 and NF-ϰB. Proc Natl Acad Sci USA 91: 2225–2229
Zhang Y, Rom WN (1993) Regulation of the interleukin-1β gene by mycobacterial components and lipopolysacharide is mediated by two NF-IL6-like motifs. Mol Cell Biol 13: 3831–3837
Duh E, Maury W, Folks T, Fauci A, Rabson A (1989) Tumor necrosis factor α activates human immunodeficiency virus type 1 through induction of nuclear factor binding on the NF-ϰB sites in the long terminal repeat. Proc Natl Acad Sci USA 86: 5974–5978
Bernstein MS, Tong-Starksen SE, Locksley RM (1991) Activation of human monocyte-derived macrophages with lipopolysaccharide decreases human immunodeficiency virus replication at the level of gene expression. J Clin Invest 88: 340–545
Goletti A, Kinter P, Biswas P, Bende S, Poli G, Fauci A (1995) Effects of cellular differentiation on cytokine-induced expression on human immunodeficiency virus in chronically infected promonocytic cells: dissociation of cellular differentiation and viral expression. J Virol 69: 2540–2546
Rich E, Chen I, Zack J, Leonard M, O’Brien W (1992) Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1. J Clin Invest 89: 176–183
Shattock R, Friedland J, Groffin G (1994) Phagocytosis ofMycobacterium tuberculosis modulates human immunodeficiency virus replication in human monocytic cells. J Gen Virol: 75 849–856
Zhang Y, Nakata K, Weiden M, Rom WN (1995)Mycobacterium tuberculosis enhances HIV-1 replication by transcriptional activation of the long terminal repeat. J Clin Invest 95: 2324–2331
Lederman M, Georges D, Kusner D, Mudido P, Giam C, Toossi Z (1994)Mycobacterium tuberculosis and its purified protein derivative activate expression of human immunodeficiency virus. J Acquir Immun Deficiency Syndrome 7: 727–733
Garrait V, Cadranel J, Esvant H, et al (1997) Tuberculosis generates a microenvironment enhancing the productive infection of local lymphocytes by HIV. J Immunol 159: 2824–2830
Toossi Z, Nicolacakis K, Xia L, Ferrari NA, Rich EA (1997) Activation of latent HIV-1 by Mycobacterium tuberculosis and its purified protein derivative in alveolar macrophages from HIV-infected individuals in vitro. J Acquir Immune Defic Syndr Hum Retrovirol 15: 325–331
Jones BE, Young SMM, Antoniskis D, Davidson PT, Kramer F, Barnes PF (1993) Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 148: 1292–1297
Chaisson RE, Slutkin G (1989) Tuberculosis and human immunodeficiency virus infection. J Infect Dis 159: 96–100
Hopewell PC (1989) Tuberculosis and human immunodeficiency virus infection. Semin Respir Infect 4: 111–122
Pitchenik AE, Fertel D (1992) Tuberculosis and nontuberculous mycobacterial disease. Med Clin North Am 76: 121–171
De Cock KM, Soro B, Coulibaly IM, Lucas SB (1992) Tuberculosis and HIV infection in sub-Saharan Africa. JAMA 268: 1581–1587
Pitchenik AE, Burr J, Suarez M, Fertel D, Gonzalez G, Moas C (1987) Human T-cell lymphotropic virus-III (HTLV-III) seropositivity and related disease among 71 consecutive patients in whom tuberculosis was diagnosed. A prospective study. Am Rev Respir Dis 135: 875–879
Theuer CP, Hopewell PC, Elias D, Schecter GF, Rutherford G, Chaisson RE (1990) Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis 162: 8–12
Rieder HL, Cauthen GM, Bloch AB, et al (1989) Tuberculosis and acquired immunodeficiency syndrome — Florida. Arch Intern Med 149: 1268–1273
Long R, Scalcini M, Manfreda J, et al (1991) Impact of human immunodeficiency virus type 1 on tuberculosis in rural Haiti. Am Rev Respir Dis 143: 69–73
Tsicopoulos A, Hamid Q, Varney V, et al (1992) Preferential messenger RNA expression of Thl-type cells (IFN-γ+, IL-2+) in classical delayed-type (tuberculin) hypersensitivity reactions in human skin. J Immunol 148: 2058–2061
Fee MJ, Oo MM, Gabayan AE, Radin DR, Barnes PF (1995) Abdominal tuberculosis in patients infected with the human immunodeficiency virus. Clin Infect Dis 20: 938–944
Dube MP, Holtom PD, Larsen RA (1992) Tuberculosis meningitis in patients with and without human immunodeficiency virus infection. Am J Med 93: 520–524
Chaisson RE, Schecter GF, Theuer ChP, Rutherford GW, Echenberg DF, Hopewell PC (1987) Tuberculosis in patients with the acquired immunodeficiency syndrome. Am Rev Respir Dis 136: 570–574
Pitchenik AE, Rubinson HA (1985) The radiographic appearance of tuberculosis in patients with the acquired immune deficiency syndrome (AIDS) and pre-AIDS. Am Rev Respir Dis 131: 393–396
Louie E, Rice LB, Holzman RS (1986) Tuberculosis in non-Haitian patients with acquired immunodeficiency syndrome. Chest 90: 542–545
Batungwanayo J, Taelman H, Dhote R, Bogaerts J, Allen S, Van De Perre P (1992) Pulmonary tuberculosis in Kigali, Rwanda: impact of human immunodeficiency virus infection on clinical and radiographic presentation. Am Rev Respir Dis 146: 53–56
Shafer RW, Chirgwin KD, Glatt AE, Dahdouh MA, Landesman SH, Suster B (1991) HIV prevalence, immunosuppression, and drug resistance in patients with tuberculosis in an area endemic for AIDS. AIDS 5: 399–405
Barnes PF, Leedom JM, Chan SF, et al (1988) Predictors of short-term prognosis in patients with pulmonary tuberculosis. J Infect Dis 158: 366–371
Alland D, Kalkut GE, Moss AR, et al (1994) Transmission of tuberculosis in New York City: an analysis of DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 330: 1710–1716
Small PM, Hopewell PC, Signh SP, et al (1994) The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 330: 1703–1709
Daley CL (1995) The typically ‘atypical’ radiographic presentation of tuberculosis in advanced HIV disease [editorial]. Tuber Lung Dis 76: 475–476
Perlman DC, El-Sadr WM, Nelson TE, et al (1997) Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. Clin Infect Dis 25: 242–246
Mukadi Y, Perriëns JH, Louis ME, et al (1993) Spectrum of immunodeficiency in HIV-I-infected patients with pulmonary tuberculosis in Zaire. Lancet 342: 143–146
Pastores SM, Naidich DP, Aranda CP, McGuinnes G, Rom WN (1993) Intrathoracic adenopathy associated with pulmonary tuberculosis in patients with human immunodeficiency virus infection. Chest 103: 1433–1437
Keiper MD, Beumont M, Elshami A, Langlotz CP, Miller WT Jr (1995) CD-T lymphocyte count and the radiographic presentation of pulmonary tuberculosis: a study of the relationship between these factors in patients with human immunodeficiency virus infection. Chest 107: 74–80
Post FA, Wood R, Pillay GP (1995) Pulmonary tuberculosis in HIV infection: radiographic appearance is related to CD4+ T-Lymphocyte count. Tubercle Lung Dis 76: 518–521
Levy H, Feldman C, Sacho H, van der Meulen H, Kallenbach J, Koornhof H (1989) A reevaluation of sputum microscopy and culture in the diagnosis of pulmonary tuberculosis. Chest 95: 1193–1197
Gordin F, Slutkin G (1990) The validity of acid-fast smears in the diagnosis of pulmonary tuberculosis. Arch Pathol Lab Med 114: 1025–1027
Kramer F, Modilevsky T, Waliany A, Leedom J, Barnes P (1990) Delayed diagnosis of tuberculosis in patients with human immunodeficiency virus infection. Am J Med 89: 451–456
Greenbaum M, Beyt BE, Murray PR (1980) The accuracy of diagnosing tuberculosis at a large teaching hospital. Am Rev Respir Dis 121: 477–481
Klein N, Duncanson F, Lenox T, Pitta A, Cohen S, Wornser G (1989) Use of mycobacterial smears in the diagnosis of pulmonary tuberculosis in AIDS/ARC patients. Chest 95: 190–192
Middlebrook G, Reggiardo Z, Tigert WD (1977) Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media. Am Rev Respir Dis 115: 1066–1071
Aliyu MH, Salihu HM (2003) HIV infection and Sputum-culture conversion in patients diagnosed withMycobacterium tuberculosis: a population-based study. Wien Klin Wochenschr 115: 340–346
Kennedy DJ, Lewis WP, Barnes PJ (1992) Yield of bronchoscopy for the diagnosis of tuberculosis in patients with human immunodeficiency virus infection. Chest 102: 1040–1044
Steele BA, Daniel TM (1991) Evaluation of the potential role of serodiagnosis of tuberculosis in a clinic in Bolivia by decision analysis, Am Rev Respir Dis 143: 713–716
Eisenstein BI (1990) The polymerase chain reaction: a new diagnostic method of using molecular genetics for medical diagnosis. N Engl J Med 322: 178–183
Thierry D, Brisson-Noel A, Vincent-Levy-Frebault V, Nguyen D, Guesdon JL, Gicquet B (1990) Characterisation of aMycobacterium tuberculosis insertion sequence, IS6110, and its application in diagnosis. J Clin Microbiol 28: 2668–2673
Catanzaro A, Davidson BL, Fujiwara PI, et al (1997) Rapid diagnostic tests for tuberculosis: what is the appropriate use? Am J Respir Crit Care Med 155: 1804–1814
Wilson S, McNerney R, Nye P, Godfrey-Faussett Stoker N, Voller A (1993) Progress toward a simplified polymerase chain reaction and its application to diagnosis of tuberculosis. J Clin Microbiol 31: 776–782
Shanker P, Manjunath N, Mohan KK, Prasad K, Behari SM, Ahula GK (1991) Rapid diagnosis of tuberculosis meningitis by polymerase chain reaction. Lancet 337: 5–7
Brindle R, Nunn PP, Githui W, Allen BW, Gathua S, Waiyaki P (1993) Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Am Rev Respir Dis 147: 958–961
Chaisson RE, Clemont HC, Holt EA, et al (1996) Sixmonth supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1154: 1034–1038
Perriëns JH, St Louis ME, Mukadi YB, et al (1995) Pulmonary tuberculosis in HIV-infected patients in Zaire: a controlled trial of treatment for either 6 or 12 months. N Engl J Med 332: 779–784
Pulido F, Pena J-M, Rubio R, et al (1997) Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 157: 227–232
Hammer SM, Squires KE, Hughes MD, et al (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 337: 725–733
Molla A, Korneyeva M, Gao Q, et al (1996) Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 2: 760–766
Havlir D, Cheeseman SH, McLaughlin M, et al (1995) High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 171: 537–545
Munsiff SS, Joseph S, Ebrahimzadeh A, Frieden TR (1997) Rifampicin-monoresistant tuberculosis in New York City, 1993–1994. Clin Infect Dis 25: 1465–1467
Lutfey M, Della-Latta P, Kapur V, et al (1996) Independent origin of mono-rifampin-resistant My cobacterium tuberculosis in patients with AIDS. Am J Respir Crit Care Med 153: 837–840
Ridzon R, Whitney CG, McKenna MT, et al (1998) Risk factors for rifampicin mono-resistant tuberculosis. Am J Respir Crit Care Med 157: 1881–1884
Peloquin CA, Nitta AT, Burman WJ, et al (1996) Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 30: 919–925
Barditch-Crovo P (1999) The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther 65: 428–438
Blaschke TF, Skinner MH (1996) The clinical pharmacokinetics of rifabutin. Clin Infect Dis 22 [Suppl 1]: S15–21
Hamzeh FM, Benson C, Gerber J, et al (2003) Steadystate pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther 73: 159–169
Choudhri SH, Hawken M, Gathua S, et al (1997) Pharcokinetics of anti-mycobacterial drugs in patients with tuberculosis. AIDS, and diarrhea. Clin Infect Dis 25: 104–111
Ackah AN, Coulibaly D, Digbeu H, et al (1995) Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d’lvoire. Lancet 345: 607–610
Chien JW, Johnson JL (1998) Paradoxical reactions in HIV and pulmonary TB. Chest 114: 933–936
Wendel KA, Alwood KS, Gachuhi R, et al (2001) Paradoxical worsening of Tuberculosis in HIV-infected persons.Chest 120: 193–197
Narita M, Ashkin D, Hollender ES, et al (1998) Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 158: 157–161
Nunn P, Brindle L, Carpenter J, et al (1992) Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya: analysis of early (six-month) mortality. Am Rev Respir Dis 146: 849–854
Whalen C, Okwera A, Johnson J, et al (1996) Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. Am J Respir Crit Care Med 153: 1977–1981
Pablos-Méndez A, Sterling TR, Frieden TR (1996) The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 276: 1223–1228
Perriëns JH, Colebunders RL, Karahunga C, et al (1991) Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with “standard” chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 144: 750–755
Richter C, Koelemay MJW, Swai ABM, Perenboom R, Mwakyusa DH, Oosting J (1995) Predictive markers of survival in HIV-seropositive and HIV-seronegative Tanzanian patients with extrapulmonary tuberculosis. Tubercle and Lung Dis 76: 510–517
Whalen C, Horsburgh R, Hom D, Lahart C, Simberkoff M, Ellner J (1995) Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 151: 129–135
Whalen C, Horsburgh R, Hom D, Lahart C, Simberkoff M, Ellner J (1997) Site of disease and opportunistic infection predict survival in HIV-associated tuberculosis. AIDS 11: 455–460
Connolly C, Reid A, Davies G, Sturm W, McAdam KP, Wilkinson D (1999) Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS 13: 1543–1547
Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P (1999) Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Care Med 159: 733–740
Whalen CC, Nsubuga P, Okwera A, et al (2000) Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 14: 1219–1228
Jones BE, Otaya M, Antoniskis D, et al (1994) A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 150: 1499–1502
Toossi Z, Sierra-Madero JG, Blinkhorn RA, Mettler MA, Rich EA (1993) Enhanced susceptibility of blood monocytes from patients with pulmonary tuberculosis to productive infection with human immunodeficiency virus type I. J Exp Med 177: 1511–1516
Valone SE, Rich EA, Wallis RS, Ellner JJ (1988) Expression of tumor necrosis factor in vitro by human mononnuclear phagocytes stimulated with whole Mycobacterium bovis BCG and Mycobacterial antigens. Infect Immunol 56: 3313–3315
Barnes PF, Fong S-J, Brennan PJ, Twomey PE, Mazumder A, Modlin RL (1990) Local production of tumor necrosis factor and interferong in tuberculous pleuritis. J Immunol 145: 149–154
Matsuyama T, Kobayashi N, Yamamoto N (1991) Cytokines and HIV infection: is AIDS a tumor necrosis factor disease. AIDS 5: 1405–1417
Munsiff SS, Alpert PL, Gourevitch MN, Chang CJ, Klein RS (1998) A prospective study of tuberculosis and HIV disease progression. JAIDS 19: 361–366
Dannenburg AM (1991) Delayed hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis. Immunol Today 12: 228–233
Markowitz N, Hansen NI, Wilcosky TC, et al (1993) Tuberculi and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 119: 185–193
Shafer RW, Kim DS, Weiss JP, Quale JM (1991) Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine 70: 384–397
Berenguer J, Moreno S, Laguna F, et al (1992) Tuberculosis meningitis in patients infected with the human immunodeficiency virus. N Engl J Med 326: 668–672
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aliyu, M.H., Salihu, H.M. Tuberculosis and HIV disease: Two decades of a dual epidemic. Wien Klin Wochenschr 115, 685–697 (2003). https://doi.org/10.1007/BF03040884
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03040884